Submission of 44th Annual Report for the Financial Year 2024-25 under Regulation 34(1) of SEBI (LODR) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mercury Laboratories Ltd has submitted its 44th Integrated Annual Report and AGM Notice for FY 2024-25 to BSE under SEBI LODR Regulation 34(1). The 44th AGM is scheduled for Wednesday, August 13, 2025 at 11:30 AM via video conferencing. The Board's Report indicates a marginal decline in revenue to ₹7,510.12 lakhs (from ₹7,555.90 lakhs in FY 2023-24), with PAT falling sharply to ₹314.49 lakhs (from ₹565.42 lakhs) and EPS dropping to ₹26.21 (from ₹47.12). The Managing Director attributed the decline to weaker domestic sales, while export segment showed strong growth. The Board has proposed a dividend of ₹3.50 per equity share of ₹10 face value for FY 2024-25. Key AGM items include re-appointment of Mr. Rajendra R Shah as MD for 3 years from April 1, 2026, appointment of Mr. Sanjay Patel as Independent Director for 5 years, and appointment of M/s. Dholakia & Associates LLP as Secretarial Auditor for FY 2025-26 to 2029-30.
The filing is a routine regulatory submission of the annual report. However, the embedded financials reveal a concerning trend — declining revenue, sharply lower PAT (-44%) and EPS (-44%) YoY — which may weigh on investor sentiment. The proposed ₹3.50 dividend offers some support, but shareholders should note the weak domestic performance offsetting strong export growth.